JNJ

170.73

-0.23%↓

NVS

117.78

-0.02%↓

ABT

130.77

+0.52%↑

TMO

466.56

-0.22%↓

ISRG

476.87

-1.3%↓

JNJ

170.73

-0.23%↓

NVS

117.78

-0.02%↓

ABT

130.77

+0.52%↑

TMO

466.56

-0.22%↓

ISRG

476.87

-1.3%↓

JNJ

170.73

-0.23%↓

NVS

117.78

-0.02%↓

ABT

130.77

+0.52%↑

TMO

466.56

-0.22%↓

ISRG

476.87

-1.3%↓

JNJ

170.73

-0.23%↓

NVS

117.78

-0.02%↓

ABT

130.77

+0.52%↑

TMO

466.56

-0.22%↓

ISRG

476.87

-1.3%↓

JNJ

170.73

-0.23%↓

NVS

117.78

-0.02%↓

ABT

130.77

+0.52%↑

TMO

466.56

-0.22%↓

ISRG

476.87

-1.3%↓

Search

Regulus Therapeutics Inc

Fermé

0

Résumé

Variation du prix de l'action

24h

Actuel

Min

Max

Chiffres clés

By Trading Economics

Revenu

3.2M

-9.6M

Ventes

340K

340K

Marge bénéficiaire

-2,833.529

Employés

34

EBITDA

2.2M

-11M

Recommandations

By TipRanks

Recommandations

Neutre

Prévisions sur 12 Mois

+4.17% upside

Dividendes

By Dow Jones

Prochains Résultats

6 août 2025

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

330M

565M

Ouverture précédente

0

Clôture précédente

0

Regulus Therapeutics Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

30 avr. 2025, 16:35 UTC

Principaux Mouvements du Marché
Acquisitions, Fusions, Rachats

Regulus Shares Surge on $1.7 Billion Acquisition by Novartis

30 avr. 2025, 11:55 UTC

Acquisitions, Fusions, Rachats

Novartis to Acquire MicroRNA-Technology Specialist Regulus for Up to $1.7 Billion

30 avr. 2025, 11:54 UTC

Acquisitions, Fusions, Rachats

Novartis to Acquire Regulus in $1.7 Billion Deal

27 mai 2025, 12:04 UTC

Acquisitions, Fusions, Rachats

Correct: Novartis Will Offer $7.00 in Cash Per Share

27 mai 2025, 12:01 UTC

Acquisitions, Fusions, Rachats

Novartis: Offer Will Expire on June 24

27 mai 2025, 12:00 UTC

Acquisitions, Fusions, Rachats

Novartis Will Offer $0.001 Per Share

27 mai 2025, 11:59 UTC

Acquisitions, Fusions, Rachats

Novartis: Offer Is to Acquire All Outstanding Shares of Regulus Therapeutics's Common Stock

27 mai 2025, 11:59 UTC

Acquisitions, Fusions, Rachats

Novartis: Redwood Merger Sub Inc. Is an Indirect Wholly Owned Subsidiary of Novartis

27 mai 2025, 11:58 UTC

Acquisitions, Fusions, Rachats

Novartis: Redwood Merger Sub Inc. Has Commenced a Tender Offer

27 mai 2025, 11:57 UTC

Acquisitions, Fusions, Rachats

Novartis Announces Commencement of Tender Offer to Buy Regulus Therapeutics

30 avr. 2025, 11:40 UTC

Acquisitions, Fusions, Rachats

Novartis to Acquire MicroRNA-Technology Specialist Regulus for Up to $1.7 Bln

30 avr. 2025, 11:39 UTC

Acquisitions, Fusions, Rachats

Novartis to Acquire Regulus in $1.7B Deal

30 avr. 2025, 11:16 UTC

Acquisitions, Fusions, Rachats

Novartis: Transaction Is Expected to Close in Second Half of 2025

30 avr. 2025, 11:15 UTC

Acquisitions, Fusions, Rachats

Novartis: Regulus Therapeutics Is U.S. Biotech Focused on microRNA Therapeutics

30 avr. 2025, 11:14 UTC

Acquisitions, Fusions, Rachats

Novartis: Transaction Includes USD0.8B Upfront Payment, Potential Additional USD 0.9B Payment

30 avr. 2025, 11:13 UTC

Acquisitions, Fusions, Rachats

Novartis to Buy Regulus Therapeutics

Comparaison

Variation de prix

Regulus Therapeutics Inc prévision

Objectif de Prix

By TipRanks

4.17% hausse

Prévisions sur 12 Mois

Moyen 8.5 USD  4.17%

Haut 11 USD

Bas 7 USD

Basé sur 5 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Neutre

5 ratings

0

Achat

5

Maintien

0

Vente

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Regulus Therapeutics Inc

Regulus Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17, which is in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease. The company is also developing a pipeline of preclinical drug products for target organ-selective delivery strategies. Regulus Therapeutics Inc. was incorporated in 2007 and is headquartered in San Diego, California.